Your browser doesn't support javascript.
loading
Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic.
Lendrem, B Clare; Lendrem, Dennis W; Pratt, Arthur G; Naamane, Najib; McMeekin, Peter; Ng, Wan-Fai; Allen, A Joy; Power, Michael; Isaacs, John Dudley.
Afiliación
  • Lendrem BC; Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Lendrem DW; Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
  • Pratt AG; NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle University, Newcastle upon Tyne, UK.
  • Naamane N; Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • McMeekin P; NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.
  • Ng WF; Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Allen AJ; NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.
  • Power M; Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
  • Isaacs JD; Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Pharm Stat ; 18(6): 632-635, 2019 11.
Article en En | MEDLINE | ID: mdl-31231892
ABSTRACT
The Receiver Operating Characteristic (ROC) curve and the Area Under the Curve (AUC) of the ROC curve are widely used in discovery to compare the performance of diagnostic and prognostic assays. The ROC curve has the advantage that it is independent of disease prevalence. However, in this note, we remind scientists and clinicians that the performance of an assay upon translation to the clinic is critically dependent upon that very same prevalence. Without an understanding of prevalence in the test population, even robust bioassays with excellent ROC characteristics may perform poorly in the clinic. While the exact prevalence in the target population is not always known, simple plots of candidate assay performance as a function of prevalence rate give a better understanding of the likely real-world performance and a greater understanding of the likely impact of variation in that prevalence on translation to the clinic.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Bioensayo / Biomarcadores / Pruebas Diagnósticas de Rutina Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Pharm Stat Asunto de la revista: FARMACOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Bioensayo / Biomarcadores / Pruebas Diagnósticas de Rutina Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Pharm Stat Asunto de la revista: FARMACOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido